Your browser doesn't support javascript.
loading
Enhancement of the liver's neuroprotective role ameliorates traumatic brain injury pathology.
Dai, Yongfeng; Dong, Jinghua; Wu, Yu; Zhu, Minzhen; Xiong, Wenchao; Li, Huanyu; Zhao, Yulu; Hammock, Bruce D; Zhu, Xinhong.
  • Dai Y; School of Basic Medical Science, Southern Medical University, Guangzhou 510515, China.
  • Dong J; Research Center for Brain Health, Pazhou Lab, Guangzhou 510330, China.
  • Wu Y; School of Basic Medical Science, Southern Medical University, Guangzhou 510515, China.
  • Zhu M; Research Center for Brain Health, Pazhou Lab, Guangzhou 510330, China.
  • Xiong W; Research Center for Brain Health, Pazhou Lab, Guangzhou 510330, China.
  • Li H; School of Psychology, Shenzhen University, Shenzhen 518060, China.
  • Zhao Y; Research Center for Brain Health, Pazhou Lab, Guangzhou 510330, China.
  • Hammock BD; School of Basic Medical Science, Southern Medical University, Guangzhou 510515, China.
  • Zhu X; Research Center for Brain Health, Pazhou Lab, Guangzhou 510330, China.
Proc Natl Acad Sci U S A ; 120(26): e2301360120, 2023 06 27.
Article en En | MEDLINE | ID: mdl-37339206
ABSTRACT
Traumatic brain injury (TBI) is a pervasive problem worldwide for which no effective treatment is currently available. Although most studies have focused on the pathology of the injured brain, we have noted that the liver plays an important role in TBI. Using two mouse models of TBI, we found that the enzymatic activity of hepatic soluble epoxide hydrolase (sEH) was rapidly decreased and then returned to normal levels following TBI, whereas such changes were not observed in the kidney, heart, spleen, or lung. Interestingly, genetic downregulation of hepatic Ephx2 (which encodes sEH) ameliorates TBI-induced neurological deficits and promotes neurological function recovery, whereas overexpression of hepatic sEH exacerbates TBI-associated neurological impairments. Furthermore, hepatic sEH ablation was found to promote the generation of A2 phenotype astrocytes and facilitate the production of various neuroprotective factors associated with astrocytes following TBI. We also observed an inverted V-shaped alteration in the plasma levels of four EET (epoxyeicosatrienoic acid) isoforms (5,6-, 8,9-,11,12-, and 14,15-EET) following TBI which were negatively correlated with hepatic sEH activity. However, hepatic sEH manipulation bidirectionally regulates the plasma levels of 14,15-EET, which rapidly crosses the blood-brain barrier. Additionally, we found that the application of 14,15-EET mimicked the neuroprotective effect of hepatic sEH ablation, while 14,15-epoxyeicosa-5(Z)-enoic acid blocked this effect, indicating that the increased plasma levels of 14,15-EET mediated the neuroprotective effect observed after hepatic sEH ablation. These results highlight the neuroprotective role of the liver in TBI and suggest that targeting hepatic EET signaling could represent a promising therapeutic strategy for treating TBI.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Fármacos Neuroprotectores / Lesiones Traumáticas del Encéfalo Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Fármacos Neuroprotectores / Lesiones Traumáticas del Encéfalo Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Año: 2023 Tipo del documento: Article